- Alvotech has acquired Ivers-Lee Group to enhance its capacity in pharmaceutical assembly and packaging.
- The integration supports upcoming biosimilar launches and expanding global demand.
Alvotech, a global biotech company focused on biosimilars, has announced the acquisition of Switzerland-based Ivers-Lee Group, a specialist in assembly and packaging for the pharmaceutical industry. While Ivers-Lee will remain a separate legal entity, it will be integrated into Alvotech’s Technical Operations division.
The move aims to expand Alvotech’s capabilities in anticipation of launching three biosimilars in 2025 and increasing global sales. Ivers-Lee, which has been a preferred packaging partner of Alvotech, brings GMP-licensed and FDA-approved facilities, with operations in Burgdorf, Switzerland, and Lörrach, Germany.
“Ivers-Lee has been an Alvotech preferred partner in assembly and packaging for several years. We know and trust each other very well,” said Robert Wessman, founder, chairman and CEO of Alvotech. He noted the acquisition would provide added flexibility to meet rising global demand while maintaining quality.
Peter Schüpbach, Ivers-Lee’s managing director and grandson of the company’s founder, will continue to lead the group and will also join Alvotech’s senior leadership team in Technical Operations. The company will continue offering contract manufacturing (CMO) services to existing clients, including blister packaging, stick-pack activities, and clinical supplies.
